Fewer than a tenth of individuals that would benefit from obesity jabs such as Wegovy can access them, warns the WHO as it releases its initial guidance on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is urging broader and more equitable access to this class of drugs.
According to projections, more than two billion are projected to be living with obesity by 2030 without intervention.
"The latest guidelines recognises that excess weight is a chronic disease that can be addressed with thorough and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are key hurdles to broad access to the treatments that can help people shift significant weight, explains the body.
Skinny Jab Shortage
Even in the present most optimistic case, the supply of these medications could only cover approximately 100 million people – fewer than 10% of the global need, per the WHO.
The guideline calls on governments and firms to expand availability, via strategies such as patent sharing.
The intellectual property rights on a key compound – the core ingredient of the drug Wegovy – is due to expire in multiple countries in 2026.
The Way Obesity Injections Work
GLP-1 drugs replicate a natural hormone to delay gastric emptying, curb appetite and enhance feelings of fullness so individuals eat less.
People typically start to lose weight after several weeks of commencing the once-weekly jabs.
Studies points to people may regain a significant portion a year later of halting the medication, because their normal appetite return.
Being overweight or obese raises your likelihood for experiencing health problems, such as diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight affects individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, per the WHO.
